Stock events for CorMedix, Inc. (CRMD)
CorMedix stock experienced several events in the past six months. On March 5, 2026, the stock dropped after Q4 2025 earnings missed EPS forecasts, despite revenue exceeding expectations, and the company reaffirmed its 2026 revenue guidance of $300M-$320M, which was below market consensus, leading to the stock reaching an 11-month low. On the same day, CorMedix announced a $75 million share repurchase program. On March 6, 2026, CorMedix reaffirmed its FY26 revenue view and its FY27 DefenCath sales outlook of $150M-$170M. In February 2026, the stock fluctuated between $6.125 and $7.850. Over the past year (as of March 5, 2026), the share price declined by 33.61% from $9.49 to $6.30, with a 52-week trading range of $5.60 to $17.43. On December 11, 2025, shares surged over 40% year-to-date due to strong DefenCath uptake. On November 14, 2025, CorMedix raised its FY25 guidance after strong Q3 results but acknowledged long-term risks associated with TDAPA reimbursement changes and potential pricing pressure.
Demand Seasonality affecting CorMedix, Inc.’s stock price
CorMedix, Inc. anticipates no meaningful seasonality in the demand for DefenCath, as dialysis volumes are not seasonal. Minor stocking dynamics are expected in December.
Overview of CorMedix, Inc.’s business
CorMedix, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. Its lead product, DefenCath, is an antimicrobial catheter lock solution for reducing catheter-related bloodstream infections in hemodialysis patients. CorMedix also has a pre-clinical research collaboration exploring taurolidine for rare pediatric tumors and acquired Melinta in 2025, expanding its product portfolio.
CRMD’s Geographic footprint
CorMedix Inc. is headquartered in Bridgewater, New Jersey, USA, with primary operations and revenue in the United States. The company is expanding globally, focusing on partnerships and regulatory approvals in Europe (Germany, France, UK) and the Asia-Pacific region (Japan, China, Australia).
CRMD Corporate Image Assessment
CorMedix's brand reputation is largely positive, particularly among analysts, with a consensus rating of "Strong Buy" and significant upside potential. The company is recognized as a promising player in biotechnology, driven by DefenCath's commercialization and the acquisition of Melinta. The recent stock drop following Q4 2025 earnings may have temporarily impacted investor sentiment, but it has been viewed as a strategic entry point. There have been no explicit reports of events negatively affecting CorMedix's brand reputation in the past year.
Ownership
CorMedix, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors, including BlackRock, Inc., Deep Track Capital, LP, and Vanguard Group Inc, hold approximately 24.94% to 33.93% of the stock. Insiders own around 2.90%, while public companies and individual investors hold an estimated 72.16% of the stock.
